Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage.

We investigated the neuroprotective effects of fasudil's active metabolite, hydroxyfasudil, a Rho-kinase inhibitor, in a rat stroke model in which endothelial damage and subsequent thrombotic occlusion were selectively induced in perforating arteries. By examining the effects on the endothelial damage/dysfunction, we thought to explore the mechanism of Rho-kinase inhibitors. Hydroxyfasudil (10mg/kg, i.p., once daily for 3 days) significantly improved neurological functions and reduced the size of the infarct area produced by internal carotid artery injection of sodium laurate in a rat cerebral microthrombosis model. Treatment with fasudil or hydroxyfasudil concentration-dependently inhibited tumor necrosis factor alpha-induced tissue factor expression on the surface of cultured human umbilical vein endothelial cells. They also inhibited thrombin-induced endothelial hyperpermeability. The present findings suggest that hydroxyfasudil is efficacious in preventing brain damage associated with cerebral ischemia, and is partially responsible for fasudil's cytoprotective potential. The results also suggest that the therapeutic benefits against ischemic injury of Rho-kinase inhibitors are attributed, at least in part, to activity upon endothelial damage/dysfunction.

Synthesis, structures, and properties of group 9- and group 10-group 6 heterodinuclear nitrosyl complexes.

The reaction of the group 9 bis(hydrosulfido) complexes [Cp*M(SH)2(PMe3)] (M=Rh, Ir; Cp*=eta(5)-C 5Me5) with the group 6 nitrosyl complexes [Cp*M'Cl2(NO)] (M'=Mo, W) in the presence of NEt3 affords a series of bis(sulfido)-bridged early-late heterobimetallic (ELHB) complexes [Cp*M(PMe3)(mu-S)2M'(NO)Cp*] (2a, M=Rh, M'=Mo; 2b, M=Rh, M'=W; 3a, M=Ir, M'=Mo; 3b, M=Ir, M'=W). Similar reactions of the group 10 bis(hydrosulfido) complexes [M(SH)2(dppe)] (M=Pd, Pt; dppe=Ph 2P(CH2) 2PPh2), [Pt(SH)2(dppp)] (dppp=Ph2P(CH2) 3PPh2), and [M(SH)2(dpmb)] (dpmb=o-C6H4(CH2PPh2)2) give the group 10-group 6 ELHB complexes [(dppe)M(mu-S)2M'(NO)Cp*] (M=Pd, Pt; M'=Mo, W), [(dppp)Pt(mu-S)2M'(NO)Cp*] (6a, M'=Mo; 6b, M'=W), and [(dpmb)M(mu-S)2M'(NO)Cp*] (M=Pd, Pt; M'=Mo, W), respectively. Cyclic voltammetric measurements reveal that these ELHB complexes undergo reversible one-electron oxidation at the group 6 metal center, which is consistent with isolation of the single-electron oxidation products [Cp*M(PMe3)(mu-S)2M'(NO)Cp*][PF6] (M=Rh, Ir; M'=Mo, W). Upon treatment of 2b and 3b with ROTf (R=Me, Et; OTf=OSO 2CF 3), the O atom of the terminal nitrosyl ligand is readily alkylated to form the alkoxyimido complexes such as [Cp*Rh(PMe3)(mu-S)2W(NOMe)Cp*][OTf]. In contrast, methylation of the Rh-, Ir-, and Pt-Mo complexes 2a, 3a, and 6a results in S-methylation, giving the methanethiolato complexes [Cp*M(PMe3)(mu-SMe)(mu-S)Mo(NO)Cp*][BPh 4] (M=Rh, Ir) and [(dppp)Pt(mu-SMe)(mu-S)Mo(NO)Cp*][OTf], respectively. The Pt-W complex 6b undergoes either S- or O-methylation to form a mixture of [(dppp)Pt(mu-SMe)(mu-S)W(NO)Cp*][OTf] and [(dppp)Pt(mu-S) 2W(NOMe)Cp*][OTf]. These observations indicate that O-alkylation and one-electron oxidation of the dinuclear nitrosyl complexes are facilitated by a common effect, i.e., donation of electrons from the group 9 or 10 metal center, where the group 9 metals behave as the more effective electron donor.

Synthesis and reactivities of a bis(cyanamido)-capped triruthenium complex.

The tetraruthenium complex [Cp*RuCl]4 (Cp* = eta(5)-C(5)Me(5)) reacts with Na(2)NCN to afford the anionic bis(cyanamido)-capped triruthenium complex [(Cp*Ru)3(micro(3)-NCN)(2)]- ((2-)), which undergoes single electron oxidation to form [(Cp*Ru)3(micro(3)-NCN)2] upon workup with 1 equiv. of [Cp(2)Fe](PF(6)) (Cp = eta(5)-C(5)H(5)). Treatment of (2-) with 1 equiv. of HCl at room temperature leads to the protonation of one of the Ru-Ru edges to give the hydrido-bridged complex [(Cp*Ru)3(micro-H)(micro-NCN)2], while the cationic side-on NCNH(2) complex [(Cp*Ru)3(micro-Cl)(micro(3)-NCN)(micro(3)-NCNH(2)-1kappaC,N:2kappaC:3kappaN)]Cl (5) is obtained by the reaction of (2-) with an excess amount of HCl at -78 degrees C. On the other hand, the reaction of (2-) with BR(3) (R = Et, Ph) results in the ligation of two BR(3) molecules to the terminal nitrogen atoms of the cyanamido ligands to yield the bis(borane) adduct (PPN)[(Cp*Ru)(3){(micro(4)-NCN)(BR(3))}(2)] (6, PPN = Ph(3)PNPPPh(3)). 6b (R = Et) slowly liberates one BEt(3) molecule in acetone to give the mono(borane) adduct (PPN)[(Cp*Ru)3(micro(3)-NCN){(micro(4)-NCN)(BEt(3))}] (7). (2-) is also shown to react with [AuCl(PPh(3))] or PhCOCl to afford the tetranuclear heterometallic complex [(Cp*Ru)3(micro(3)-NCN){(micro(4)-NCN)(AuPPh(3))}] (8) or the benzoylcyanamido complex [(Cp*Ru)3(micro(3)-NCN)(micro(3)-NCNCOPh)] in which the Au(PPh(3))+ or benzoyl fragment is bound to the terminal nitrogen atom of a cyanamido ligand. The molecular structures of PPN+(2-), 5.C(6)H(6), 7 and 8.C(6)H(6) have been determined by single-crystal X-ray analyses.

Wide therapeutic time window for fasudil neuroprotection against ischemia-induced delayed neuronal death in gerbils.

The neuroprotective potential and therapeutic time window for fasudil, a Rho-kinase inhibitor (RKI), were evaluated for delayed neuronal death in gerbils. A preliminary screening was done on fasudil, ozagrel, and edaravone using a single administration in a delayed neuronal death study. Intraperitoneal (i.p.) administration of edaravone, a free radical scavenger (3, 10 mg/kg) immediately after re-circulation did not reduce neuronal degeneration. We previously reported that ozagrel, a thromboxane A(2) synthetase inhibitor (30 mg/kg) also did not reduce neuronal degeneration, while fasudil (3, 30 mg/kg) significantly protected against the ischemia-induced neuronal loss. To clarify the therapeutic time window of fasudil, which showed a positive effect in a preliminary screening, animals received their first i.p. administration of fasudil (10 mg/kg) 24 or 48 h after ischemia. Administration of fasudil twice daily was continued until day 6. Fasudil significantly protected against the ischemia-induced delayed neuronal death when the treatment was started 24 h after ischemia. In gerbils, hydroxyfasudil, an active metabolite of fasudil, was found following an i.p. administration of fasudil (10 mg/kg), and the value of the area under the plasma level curve of hydroxyfasudil was 7 times higher than that of fasudil. Hydroxyfasudil may contribute to the potency of fasudil. The present findings indicate that the RKI fasudil reduces ischemic neuronal damage with a wide therapeutic time window in gerbil, and may be useful in the treatment of acute ischemic stroke in humans.

Synthesis, structures, and solution behavior of di- and trinuclear titanium(IV)--cyclophosphato complexes.

The reaction of the cyclotetraphosphate ion (P(4)O(12)(4)(-)) with [CpTiCl(3)] (Cp = eta(5)-C(5)Me(5)) gives [(CpTi)(2)(P(4)O(12))(2)](2)(-) where the P(4)O(12) ligands adopt a saddle conformation, while that with [(CpTiCl)(3)(mu-O)(3)] leads to [(CpTi)(3)(mu-O)(3)(P(4)O(12))](-) containing a crown form P(4)O(12) ligand; both products feature their unique cage structures. On the other hand, the reactions of the cyclotriphosphate ion (P(3)O(9)(3)(-)) with [(CpTiCl(2))(2)(mu-O)] and [(CpTiCl)(3)(mu-O)(3)] afford [(CpTi)(2)(mu-O)(P(3)O(9))(2)](2)(-) and [(CpTi)(3)(mu-O)(3)Cl(P(3)O(9))](-), respectively, and in both cases the P(3)O(9) ligands bridge two titanium centers with an eta(2):eta(1) mode.

Synthesis and structure of 1-zirconacyclopent-3-yne complexes without substituents adjacent to the triple bond.

Five-membered metallacyclic alkynes that have no substituents adjacent to the triple bond have been synthesized, isolated, and structurally characterized. Zirconocene dichlorides, Cp'2ZrCl2 (Cp' = C5H5, C5H4-t-Bu), reacted with 1,4-dichlorobut-2-yne in the presence of magnesium to give 1-zirconacyclopent-3-yne compounds (5 (a) Cp' = C5H5, (b) Cp' = C5H4-t-Bu) that have a -CH2CCCH2- moiety in good yields. They are stable enough to be isolated in a pure form, despite the absence of substituents. 5a reacted with an equimolar amount of Cp2Zr(but-1-ene)(PMe3) to produce a bimetallic complex in which the zirconacyclopentyne coordinates to the other zirconocene moiety as an alkyne.

Synthesis and characterization of cyclotetraphosphato complexes of Rh(I), Ir(I), Ru(II), and Pd(II).

The cyclotetraphosphate ion (P(4)O(12)(4)(-)) as a PPN (PPN = (PPh(3))(2)N(+)) salt reacts with [MCl(cod)](2) (M = Rh, Ir; cod = 1,5-cyclooctadiene) to give the dinuclear complexes (PPN)(2)[[M(cod)](2)(P(4)O(12))], in which the two metal moieties are situated trans to each other with respect to the P(4)O(4) ring in the solid state. In solution, however, these complexes exist as mixtures of trans and cis isomers. On the other hand, the P(4)O(12)(4)(-) ion reacts with 4 equiv of [Rh(cod)(MeCN)(x)](+) cation to give the tetranuclear complex [[Rh(cod)](4)(P(4)O(12))], where the four Rh(cod) fragments are bound to the P(4)O(12) platform alternately on both sides of the P(4)O(4) ring. Dinuclear P(4)O(12) complexes of ruthenium and palladium are also synthesized.